dc.contributor.author | Lee, GA | |
dc.contributor.author | Aktaa, S | |
dc.contributor.author | Baker, E | |
dc.contributor.author | Gale, CP | |
dc.contributor.author | Yaseen, IF | |
dc.contributor.author | Gulati, G | |
dc.contributor.author | Asteggiano, R | |
dc.contributor.author | Szmit, S | |
dc.contributor.author | Cohen-Solal, A | |
dc.contributor.author | Abdin, A | |
dc.contributor.author | Jurczak, W | |
dc.contributor.author | Garrido Lopez, P | |
dc.contributor.author | Sverdlov, AL | |
dc.contributor.author | Tocchetti, CG | |
dc.contributor.author | Barac, A | |
dc.contributor.author | Parrini, I | |
dc.contributor.author | Zamorano, P | |
dc.contributor.author | Iakobishvili, Z | |
dc.contributor.author | Pudil, R | |
dc.contributor.author | Badimon, L | |
dc.contributor.author | Kirby, AM | |
dc.contributor.author | Blaes, AH | |
dc.contributor.author | Farmakis, D | |
dc.contributor.author | Curigliano, G | |
dc.contributor.author | Stephens, R | |
dc.contributor.author | Lyon, AR | |
dc.contributor.author | Lopez-Fernandez, T | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2023-01-04T12:42:12Z | |
dc.date.available | 2023-01-04T12:42:12Z | |
dc.date.issued | 2022-12-13 | |
dc.identifier | 6783158 | |
dc.identifier.citation | European Heart Journal - Quality of Care and Clinical Outcomes, 2022, 9 (1), pp. 1 - 7 | |
dc.identifier.issn | 2058-5225 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5634 | |
dc.identifier.eissn | 2058-1742 | |
dc.identifier.eissn | 2058-1742 | |
dc.identifier.doi | 10.1093/ehjqcco/qcac070 | |
dc.description.abstract | AIMS: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. METHODS AND RESULTS: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. CONCLUSION: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes. | |
dc.format | Print | |
dc.format.extent | 1 - 7 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Oxford University Press (OUP) | |
dc.relation.ispartof | European Heart Journal - Quality of Care and Clinical Outcomes | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
dc.subject | Assessment | |
dc.subject | Cancer therapy-related cardiovascular toxicity | |
dc.subject | Cardio-oncology | |
dc.subject | Outcomes | |
dc.subject | Quality indicators | |
dc.subject | Treatment | |
dc.subject | Humans | |
dc.subject | Quality Indicators, Health Care | |
dc.subject | Cardiology | |
dc.subject | Medical Oncology | |
dc.subject | Neoplasms | |
dc.title | European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-10-21 | |
dc.date.updated | 2023-01-04T12:40:59Z | |
rioxxterms.version | NA | |
rioxxterms.versionofrecord | 10.1093/ehjqcco/qcac070 | |
rioxxterms.licenseref.startdate | 2022-12-13 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36316010 | |
pubs.issue | 1 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.) | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1093/ehjqcco/qcac070 | |
pubs.volume | 9 | |
dc.contributor.icrauthor | Kirby, Anna | |
icr.provenance | Deposited by Mr Arek Surman on 2023-01-04. Deposit type is initial. No. of files: 1. Files: European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular.pdf | |